Viewing nowGabapentin Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
HK inno.N Co., Ltd.

MFDS item code 201702674 · Approved 2017.05.29 · Insurance code 640007120
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjunct for partial seizures in patients with epilepsy. It is also effective for the treatment of fibromyalgia. In other words, it helps relieve neuropathic pain, manage symptoms of epilepsy, and improve musculoskeletal pain.
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12 to 17 years because there are insufficient data on safety and efficacy.
This drug is an antiepileptic medication and carries the risk of suicidal thoughts, suicidal behavior, and mental health problems such as depression during use; thus, both the patient and caregiver should closely monitor for these symptoms. This medication should not be administered to patients with hypersensitivity to the ingredients or those with certain genetic lactase deficiency. Patients with diabetes should be cautious as weight gain while using this drug may require adjustments to their diabetes medication regimen. If symptoms of angioedema occur, such as swelling of the face or mouth, discontinue use immediately and consult healthcare professionals. Elderly patients may experience dizziness, drowsiness, or loss of consciousness, especially during the initial stages of treatment, and may also experience changes in vision such as blurred vision. Discontinuing this medication abruptly may lead to withdrawal symptoms such as insomnia, headache, and anxiety; it should be tapered gradually according to healthcare professional instructions. Patients with a history of substance abuse may have a higher risk of misuse of this medication; thus, it should be administered with caution, monitoring for signs of misuse or dependence. Patients with impaired renal function may require dosage adjustments. Patients with heart disease may exhibit congestive heart failure symptoms while taking this medication, thus warranting careful monitoring. Use with other central nervous system depressants, especially opioid analgesics, may increase the risk of respiratory depression; caution is advised. In early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or plan to become pregnant should consult healthcare professionals before use and employ effective birth control methods. During breastfeeding, this drug may pass into breast milk and affect infants, so breastfeeding should be avoided or discussed with a healthcare professional. When engaging in activities requiring alertness such as driving or operating machinery, caution is necessary due to the risk of dizziness or drowsiness from this medication. If serious skin rashes or allergic symptoms occur, discontinue use immediately and notify healthcare professionals. Overdosage may cause confusion, drowsiness, seizures, etc., requiring immediate emergency treatment; blood dialysis may be performed if necessary. Keep out of reach of children and avoid transferring to other containers to prevent quality deterioration or accident risks.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper respiratory swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, sadness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual dysesthesia, agitation, mood instability, low emotional state, elevated emotional state, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, flat affect, ataxia, coordination abnormality, balance disorder, memory loss, attention deficit, memory impairment, tremors, dysarthria, sensory abnormalities, sensory decrease, sedation, somnolence, cognitive impairment, nystagmus, language impairment, myoclonus, reduced reflexes, motor disturbances, psychomotor agitation, orthostatic dizziness, hypersensitivity, burning sensation, activity tremor, syncope, confusion, muscle weakness, olfactory abnormalities, loss of taste, writing difficulties, diplopia, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, bradycardia, paroxysmal tachycardia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, increased saliva secretion, gastroesophageal reflux, oral sensory decrease, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle spasms, arthralgia, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle cramps, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, incontinence, decreased urine, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, swelling, gait abnormalities, falls, feeling intoxicated, altered sensations, fatigue, sensation of chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase in blood, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium in blood, weight loss, increased creatinine in blood, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, apathy, delirium, paralysis (facial paralysis), affective disorder, confusion, agitation, restlessness, worsening of seizures, gastrointestinal disturbance, tinnitus, sleep disorders, skin diseases, increased BUN, blood in stool
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is important to maintain storage temperatures between 15 to 30 degrees Celsius.
Opaque capsule with upper part yellowish and lower part white, containing white or grayish-white powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
HK inno.N Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.